Neovacs S.A. (EPA:ALNEV)

Neovacs Statistics

Total Valuation

Neovacs has a market cap or net worth of EUR 906. The enterprise value is 133,055.

Market Cap	906
Enterprise Value	133,055

Important Dates

The next estimated earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	n/a

Share Statistics

Neovacs has 476,625 shares outstanding.

Current Share Class	476,625
Shares Outstanding	476,625
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.00
PB Ratio	0.00
P/TBV Ratio	0.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.03
EV / Sales	0.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.04

Financial Position

The company has a current ratio of 0.67, with a Debt / Equity ratio of 0.01.

Current Ratio	0.67
Quick Ratio	0.65
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-8.71

Financial Efficiency

Return on equity (ROE) is -23.23% and return on invested capital (ROIC) is -18.70%.

Return on Equity (ROE)	-23.23%
Return on Assets (ROA)	-10.66%
Return on Invested Capital (ROIC)	-18.70%
Return on Capital Employed (ROCE)	-29.97%
Weighted Average Cost of Capital (WACC)	301.37%
Revenue Per Employee	12,454
Profits Per Employee	-272,371
Employee Count	16
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	-1.10M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -100.00% in the last 52 weeks. The beta is -23.04, so Neovacs's price volatility has been lower than the market average.

Beta (5Y)	-23.04
52-Week Price Change	-100.00%
50-Day Moving Average	0.01
200-Day Moving Average	1.38
Relative Strength Index (RSI)	21.97
Average Volume (20 Days)	13,346,339

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Neovacs had revenue of EUR 199,267 and -4.36 million in losses. Loss per share was -9.14.

Revenue	199,267
Gross Profit	-2.91M
Operating Income	-5.71M
Pretax Income	-5.46M
Net Income	-4.36M
EBITDA	-5.52M
EBIT	-5.71M
Loss Per Share	-9.14

Balance Sheet

The company has 38,511 in cash and 170,663 in debt, with a net cash position of -132,152 or -0.28 per share.

Cash & Cash Equivalents	38,511
Total Debt	170,663
Net Cash	-132,152
Net Cash Per Share	-0.28
Equity (Book Value)	18.89M
Book Value Per Share	39.63
Working Capital	-1.31M

Cash Flow

In the last 12 months, operating cash flow was -3.09 million and capital expenditures -16,275, giving a free cash flow of -3.11 million.

Operating Cash Flow	-3.09M
Capital Expenditures	-16,275
Free Cash Flow	-3.11M
FCF Per Share	-6.53

Margins

Gross Margin	n/a
Operating Margin	-2,866.37%
Pretax Margin	-2,738.87%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neovacs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-481,008.17%
FCF Yield	-343,402.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 18, 2025. It was a reverse split with a ratio of 0.001.

Last Split Date	Jul 18, 2025
Split Type	Reverse
Split Ratio	0.001

Scores

Neovacs has an Altman Z-Score of -4.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.52
Piotroski F-Score	2